Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091975 · ClinicalTrials.gov registry record · Phase 3
Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT00091975 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 78 participants.
The verdict
NCT00091975, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety and efficacy of Zemplar® Capsule versus placebo, in decreasing elevated intact parathyroid hormone levels in chronic kidney disease stage 5 subjects with secondary hyperparathyroidism on hemodialysis or peritoneal dialysis, while using the revised dose titration scheme.
Interventions
- DRUG Zemplar Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2004-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091975
The ClinicalTrials.gov registry entry for NCT00091975 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zemplar Capsule is the first listed.
NCT00091975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091975 about?
NCT00091975 is a clinical study titled "Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis". The objective of this study is to determine the safety and efficacy of Zemplar® Capsule versus placebo, in decreasing elevated intact parathyroid hormone levels in chronic kidney disease stage 5 subjects with secondary hyperparathyroidism on hemodialysis or peritoneal dialysis, while using the revis...
What is the current status of trial NCT00091975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2004-08.
What interventions are being tested in trial NCT00091975?
The interventions under investigation include: Zemplar Capsule (DRUG).
Who is sponsoring clinical trial NCT00091975?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.